Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRAF fusion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

BRAF positive (1)

BRAF positive (1)

›

Related tests:

FoundationOne® CDx (110)

FoundationOne® CDx (110)

BRAF fusion	Glioma	BRAF fusion	Glioma	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1
BRAF fusion	Melanoma	BRAF fusion	Melanoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
BRAF fusion	Glioma	BRAF fusion	Glioma	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2
BRAF fusion	Non Small Cell Lung Cancer	BRAF fusion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
BRAF fusion	Lung Cancer	BRAF fusion	Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
BRAF fusion	Glioma	BRAF fusion	Glioma	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3	BVD-523 Sensitive: C3 – Early Trials BVD-523 Sensitive : C3
BRAF fusion	Melanoma	BRAF fusion	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
BRAF fusion	Solid Tumor	BRAF fusion	Solid Tumor	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3	cobimetinib + RG6185 Sensitive: C3 – Early Trials cobimetinib + RG6185 Sensitive : C3
BRAF fusion	Ovarian Cancer	BRAF fusion	Ovarian Cancer	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4